You are here

Article Text

Article menu
Download PDFPDF
Letters
Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands
  1. Augustin Latourte,
  2. Aline Frazier,
  3. Claire Brière,
  4. Hang-Korng Ea,
  5. Pascal Richette
  1. Fédération de Rhumatologie, Université Paris 7, UFR médicale, Assistance Publique Hôpitaux de Paris, Hôpital Lariboisière, Paris, France
  1. Correspondence to Professor Pascal Richette, Fédération de Rhumatologie, Université Paris 7, UFR médicale, Assistance Publique Hôpitaux de Paris, Hôpital Lariboisière, 2 Rue Ambroise Paré, 75475 Paris cedex 10, Paris 75010, France; pascal.richette{at}lrb.aphp.fr

http://dx.doi.org/10.1136/annrheumdis-2012-202738

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Patients with hereditary haemochromatosis (HH) may present arthralgia in the hands and large joints or severe arthropathy mimicking osteoarthritis typically involving metacarpophalangeal (MCP) joints 2 and 3.1–3 This arthropathy, which may seriously affect quality of life, was reported to occur in 20%–50% of HH patients with articular complaints and can coexist with calcium pyrophosphate deposition.4–6

    Hand arthropathy is not alleviated by phlebotomy, and in a few patients, disease is refractory or intolerant to standard treatments such as non-steroidal anti-inflammatory drugs (NSAIDs), low-dose colchicine or analgesics. Thus, these patients remain without adequate treatment.

    Given the frequent presence of local inflammatory symptoms in MCP joints and the discovery that interleukin 1β (IL-1β) plays a key role in the pathogenesis of arthritis due to …

    View Full Text

    Footnotes

    • Contributors PR and AL wrote the manuscript. AL, AF, CB and HKE helped in the management of these patients. CB performed the ultrasound.

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.